SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-9.04%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.19B
AUM Growth
+$1.19B
(-24%)
Cap. Flow
-$79.2M
Cap. Flow
% of AUM
-6.66%
Top 10 Holdings %
Top 10 Hldgs %
66.99%
Holding
79
New
10
Increased
12
Reduced
14
Closed
17
Top Buys
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$97.8M |
| 2 |
AstraZeneca
AZN
|
$36.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$24.8M |
| 4 |
Zoetis
ZTS
|
$20.1M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$19.7M |
Top Sells
| 1 |
AbbVie
ABBV
|
$42.2M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$26.3M |
| 3 |
Align Technology
ALGN
|
$25.1M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$20.9M |
| 5 |
iRhythm Technologies
IRTC
|
$19.9M |
Sector Composition
| 1 | Healthcare | 98.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $248M | 18.79% | 1,953,077 | – | – |
|
2
Natera
NTRA
$23.1B
| $126M | 9.58% | 3,102,960 | – | – |
|
|
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $97.8M | 7.42% | +5,573,949 | New | +$97.8M |
|
4
Vera Therapeutics
VERA
$1.38B
| $74.7M | 5.67% | 3,181,442 +266,666 | +9% | +$6.26M |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $68.9M | 5.23% | 3,758,686 | – | – |
|
6
Ascendis Pharma
ASND
$11.8B
| $58.7M | 4.45% | 499,824 | – | – |
|
|
7
AstraZeneca
AZN
$248B
| $36.7M | 2.79% | +553,903 | New | +$36.7M |
|
8
United Therapeutics
UTHR
$13.8B
| $35.7M | 2.71% | 199,183 +69,429 | +54% | +$12.5M |
|
9
Y-mAbs Therapeutics
YMAB
$388M
| $26.1M | 1.98% | 2,194,278 | – | – |
|
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $24.8M | 1.88% | +95,003 | New | +$24.8M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $24.5M | 1.86% | 232,894 +11,102 | +5% | +$1.17M |
|
12
DexCom
DXCM
$29.5B
| $20.6M | 1.56% | 40,265 +7,861 | +24% | +$4.02M |
|
13
Regenxbio
RGNX
$451M
| $20.4M | 1.55% | 614,085 -393,996 | -39% | -$13.1M |
|
|
14
Zoetis
ZTS
$69.3B
| $20.1M | 1.53% | +106,574 | New | +$20.1M |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $19.7M | 1.5% | +602,545 | New | +$19.7M |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $18.3M | 1.39% | 572,297 +360,016 | +170% | +$11.5M |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.2M | 1.3% | 1,021,211 +222,422 | +28% | +$3.74M |
|
18
Travere Therapeutics
TVTX
$1.56B
| $17M | 1.29% | 658,249 -382,609 | -37% | -$9.86M |
|
19
Guardant Health
GH
$8.41B
| $15.9M | 1.21% | 239,995 +7,432 | +3% | +$492K |
|
|
CCXI
20
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.4M | 1.09% | 573,684 -157,538 | -22% | -$3.95M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $13.6M | 1.03% | 176,533 +89,211 | +102% | +$6.88M |
|
22
NextCure
NXTC
$13.5M
| $13M | 0.99% | 2,671,856 | – | – |
|
23
Protagonist Therapeutics
PTGX
$3.67B
| $13M | 0.98% | 547,441 +65,184 | +14% | +$1.54M |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.5M | 0.95% | 717,064 -234,162 | -25% | -$4.07M |
|
|
CMPI
25
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $11.5M | 0.87% | 3,606,707 | – | – |
|